[go: up one dir, main page]

AR059727A1 - Moduladores de 11- beta hidroxil esteriode deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos , y metodos de uso de los mismos - Google Patents

Moduladores de 11- beta hidroxil esteriode deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos , y metodos de uso de los mismos

Info

Publication number
AR059727A1
AR059727A1 ARP070100888A ARP070100888A AR059727A1 AR 059727 A1 AR059727 A1 AR 059727A1 AR P070100888 A ARP070100888 A AR P070100888A AR P070100888 A ARP070100888 A AR P070100888A AR 059727 A1 AR059727 A1 AR 059727A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
cycloalkyl
heterocycloalkyl
nrc
alkyl
Prior art date
Application number
ARP070100888A
Other languages
English (en)
Inventor
Jincong Zhuo
Meizhong Xu
Yun-Long Li
Chunhong He
Wenqing Yao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AR059727A1 publication Critical patent/AR059727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Inhibidores de 11-beta hidroxil esteroide deshidrogenada de tipo 1 y composiciones farmacéuticas que los contienen. Los compuestos de la presente pueden ser utiles para el tratamiento de diversas enfermedades asociadas con la expresion o actividad de la 11-beta hidroxil esteroide deshidrogenada de tipo 1. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), (2), (3), (4), (5), (6) o (7), o sal aceptable para uso farmacéutico o prodroga del mismo, en donde Cy es arilo, heteroarilo, cicloalquilo, o heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2, 3, 4 o 5 -W-X-Y-Z; el átomo J que forma un anillo es N o C; L se encuentra ausente, o es alquenilenilo C1-6, (CR1R2)q, (CR1R2)q1O(CR1R2)q2, (CR1R2)q1S(CR1R2)q2, (CR1R2)q1SO2(CR1R2)q2, (CR1R2)q1SO(CR1R2)q2, (CR1 R2)q1SO2NR3(CR1R2)q2, (CR1R2)q1COO(CR1R2)q2, (CR1R2)q1CO(CR1 R2)q2, (CR1R2)q1 NR3aCONR3(CR1R2)q2, o (CR1R2)q1CONR3(CR1R2)q2, en donde el alquenilenilo C1-6 está opcionalmente sustituido por 1,2, 3, 4, 5 o 6 R1a; M1 es CH, CH2, C(O), O, SO, SO2, OC(O), NH, NHC(O), o NHSO2; M2 y M3 se seleccionan en forma independiente entre ausente, C(O), SO, SO2, O, OC(O), NH, NHC(O), y NHSO2, con la salvedad de que al menos uno de M2 y M3 es distinto de ausente; T es NR8, CH2 o O; el anillo B es un grupo cicloalquilo de 3 a 14 miembros o un grupo heterocicloalquilo de 3 a 14 miembros el cual está opcionalmente sustituido por 1, 2, 3, 4 o 5 -Wa-Xa-W'-X'-Y-Z'; ------ es una union simple o doble; RL es Cy o alquilo C1-6, en donde el alquilo C1-6 está opcionalmente sustituido por 1, 2, 3, 4 o 5 -W-X-Y-Z; R1 y R2 se seleccionan en forma independiente entre H, halo, alquilo C1-6, haloalquilo C1-6, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', Sra', C(O)Rb, C(O)NRc'Rd', C(O)ORa', OC(O)Rb, OC(O)NRC'Rd', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', y S(O)2NRc'Rd'; cada R1a se selecciona en forma independiente entre halo, alquilo C1-6, haloalquilo C1-6, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', Sra', C(O)Rb, C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', y S(O)2NRc'Rd'; R3 y R3a se seleccionan en forma independiente entre H, alquilo C1-8, arilalquilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo y heterocicloalquilalquilo, en donde cada uno de los alquilo C1-8, arilalquilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo; heterocicloalquilo y heterocicloalquilalquilo está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; R4 es H, O(O)ORb', C(O)NRc'Rd', ORb', SRb', S(O)Ra', S(O)NRc'Rd', S(O)2Ra', S(O)2NRc'Rd', alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, en donde cada uno de los alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo está opcionalmente sustituido por 1, 2 o 3 R11, R5 es H o alquilo C1-6, en donde el alquilo C1-6 está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; o R4 y R5 junto con la porcion -C-C(O)-N(R6)- interpuesta al cual están unidos forman un grupo heterocicloalquilo de 4 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z';R6 es alquilo C1-6, arilo, cicloalquilo, heteroarilo o heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2 o 3 -W'-X'-Y'-Z'; o R5 y R6 junto con el átomo de N al cual están unidos forman a un grupo heterocicloalquilo de 3 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; R7 es H, C(O)ORb', C(O)NRc'Rd', ORb', SRb', S(O)Ra', S(O)NRc'Rd', S(O)2Ra', S(O)2NRc'Rd', alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, en el alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo está opcionalmente sustituido por 1, 2 o 3 R11, R8 es H, alquilo C1-6, arilalquilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo o heterocicloalquilalquilo, en donde cada uno de los alquilo C1-6, arilalquilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo y heterocicloalquilalquilo está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; o R7 y R8 junto con los dos átomos adyacentes al cual están unidos forman a un grupo heterocicloalquilo de 3 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; R9 es H, alquilo C1-6, arilalquilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo o heterocicloalquilalquilo, en donde cada uno de los alquilo C1-6, arilalquilo, heteroarilalquilo, cicloalquilo, cicloalquilalquilo, heterocicloalquilo y heterocicloalquilalquilo está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; o R8 y R9 junto con los dos átomos adyacentes al cual están unidos forman a un grupo heterocicloalquilo de 3 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; o R7 y R9 junto con la porcion -C-T-C(O)- interpuesta al cual están unidos forman un grupo heterocicloalquilo de 4 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; o R4 y R9 junto con la porcion -C-S(O)2- interpuesta al cual están unidos forman un grupo heterocicloalquilo de 4 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; o R9 es NR9aR9b; R9a y R9b son cada uno, en forma independiente, H, alquilo C1-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, cada uno opcionalmente sustituido con 1, 2 o 3 -W'- X'-Y'-Z'; o R9a y R9b junto con el átomo de N al cual están unidos forman a un grupo heterocicloalquilo de 3 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o 3 -W'-X'-Y'-Z'; cada R10 es independientemente OC(O)Ra', OC(O)Orb', OC(O)NRc'Rd', C(O)ORb', C(O)NRc'Rd', NRc'Rd', NRc'C(O)Ra', NRc'C(O)ORb', NRc'S(O)2Rb', S(O)Ra', S(O)NRc'Rd', S(O)2Ra', S(O)2NRc'Rd', ORb', SRb', alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo o heterocicloalquilalquilo, en donde cada uno de los alquilo C1-10, haloalquilo C1-10, alquenilo C2-10, alquinilo C2-10, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, arilalquilo, heteroarilalquilo, cicloalquilalquilo y heterocicloalquilalquilo está opcionalmente sustituido por 1, 2 o 3 R11; o dos R10 junto con el mismo átomo de carbono al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de 3 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o 3 R11, o dos R10 junto con el mismo átomo de carbono al cual están unidos forman un grupo carbonilo; o dos R10 adyacentes junto con los dos átomos a los cuales están unidos forman un grupo cicloalquilo fusionado de 3 a 14 miembros o un grupo heterocicloalquilo fusionado de 3 a 14 miembros el cual está opcionalmente sustituido por R11, o R10 y -L-Cy junto con el mismo átomo de carbono al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de 3 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o3 R11, o R10 y -L-Cy adyacentes junto con los dos átomos a los cuales están unidos forman un grupo cicloalquilo fusionado de 3 a 14 miembros o un grupo heterocicloalquilo fusionado de 3 a 14 miembros el cual está opcionalmente sustituido por R11; o R10 y -L-RL junto con el mismo átomo de carbono al cual están unidos forman un grupo cicloalquilo o heterocicloalquilo de 3 a 14 miembros el cual está opcionalmente sustituido por 1, 2 o 3 R11, o R10 y -LRL adyacentes junto con los dos átomos a los cuales están unidos forman un grupo cicloalquilo fusionado de 3 a 14 miembros o un grupo heterocicloalquilo fusionado de 3 a 14 miembros el cual está opcionalmente sustituido por R11; o r4 y R10 adyacentes junto con los das átomos a los cuales están unidos forman un grupo cicloalquilo fusionado de 3 a 14 miembros o un grupo heterocicloalquilo fusionado de 3 a 14 miembros el cual está opcionalmente sustituido por R11; o R7 y R10 adyacentes junto con los dos átomos a los cuales están unidos forman un grupo cicloalquilo fusionado de 3 a 14 miembros o un grupo heterocicloalquilo fusionado de 3 a 14 miembros el cual está opcionalmente sustituido por R11; o R4 y -L-Cy adyacentes junto con los dos átomos a los cuales están unidos forman un grupo cicloalquilo fusionado de 3 a 14 miembros o un grupo heterocicloalquilo fusionado de 3 a 14 miembros el cual está opcionalmente sustituido por R11; o R7 y -L-Cy adyacentes junto con los dos átomos a los cuales están unidos forman un grupo cicloalquilo fusionado de 3 a 14 miembros o un grupo heterocicloalquilo fusionado de 3 a 14 miembros el cual está opcionalmente sustituido por R11, o R4 y -L-RL adyacentes junto con los dos átomos a los cuales están unidos forman un grupo cicloalquilo fusionado de 3 a 14 miembros o un grupo heterocicloalquilo fusionado de 3 a 14 miembros el cual está opcionalmente sustituido por R11; o R7 y -L-RL adyacentes junto con los dos átomos a los cuales están unidos forman un grupo cicloalquilo fusionado de 3 a 14 miembros o un grupo heterocicloalquilo fusionado de 3 a 14 miembros el cual está opcionalmente sustituido por R11; cada R11 es independientemente halo, alquilo C1-6, haloalquilo C1-6, arilo, cicloalquilo, heteroarilo, heterocicloalquilo, CN, NO2, ORa', SRa', C(O)Rb', C(O)NRc'Rd', C(O)ORa', OC(O)Rb', OC(O)NRc'Rd', NRc'Rd', NRc'C(O)Rd', NRc'C(O)ORa', NRc'S(O)2Rb', S(O)Rb', S(O)NRc'Rd', S(O)2Rb', o S(O)2NRc'Rd'; W, W', Wö y Wa se seleccionan en forma independiente entre ausente, alquilenilo C1-6, alquenilenilo C2-6, alquinilenilo C2-6, O, S, NRe, CO, COO
ARP070100888A 2006-03-03 2007-03-02 Moduladores de 11- beta hidroxil esteriode deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos , y metodos de uso de los mismos AR059727A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77868206P 2006-03-03 2006-03-03
US80876906P 2006-05-26 2006-05-26

Publications (1)

Publication Number Publication Date
AR059727A1 true AR059727A1 (es) 2008-04-23

Family

ID=38292680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100888A AR059727A1 (es) 2006-03-03 2007-03-02 Moduladores de 11- beta hidroxil esteriode deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos , y metodos de uso de los mismos

Country Status (4)

Country Link
US (1) US20070208001A1 (es)
AR (1) AR059727A1 (es)
TW (1) TW200806629A (es)
WO (1) WO2007103719A2 (es)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2570637A1 (en) * 2004-06-24 2006-02-02 Wenqing Yao N-substituted piperidines and their use as pharmaceuticals
JP2008504279A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
US20050288338A1 (en) * 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
WO2006002361A2 (en) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
AU2005267331A1 (en) * 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
KR20070024639A (ko) * 2004-06-24 2007-03-02 인사이트 산 디에고 인코포레이티드 아미도 화합물 및 약제로서의 이의 용도
TW200626156A (en) * 2004-08-10 2006-08-01 Incyte Corp Amido compounds and their use as pharmaceuticals
NZ554906A (en) * 2004-11-10 2011-01-28 Incyte Corp Lactam compounds and their use as pharmaceuticals
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
BRPI0518281A2 (pt) * 2004-11-18 2008-11-18 Incyte Corp inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
DE102005044814A1 (de) * 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
JP2009508963A (ja) * 2005-09-21 2009-03-05 インサイト・コーポレイション アミド化合物および医薬組成物としてのその使用
TW200804382A (en) * 2005-12-05 2008-01-16 Incyte Corp Lactam compounds and methods of using the same
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070197530A1 (en) * 2006-01-31 2007-08-23 Yun-Long Li Amido compounds and their use as pharmaceuticals
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP2013163A1 (en) * 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
EP2018378A2 (en) * 2006-05-17 2009-01-28 Incyte Corporation Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same
WO2008024497A2 (en) * 2006-08-25 2008-02-28 Vitae Pharmaceuticals, Inc. INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
JP2008188285A (ja) * 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
WO2008106128A2 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
TWI362930B (en) 2007-04-27 2012-05-01 Purdue Pharma Lp Trpv1 antagonists and uses thereof
CL2008001839A1 (es) * 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
AR067673A1 (es) * 2007-07-26 2009-10-21 Vitae Pharmaceuticals Inc Derivados de 1,3 oxazinan - 2 - ona como inhibidores ciclicos de la 11 beta -hidroxiesteroide deshidrogenasa 1. composiciones farmaceuticas.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009062200A1 (en) * 2007-11-09 2009-05-14 University Of Tennessee Research Foundation Anti-inflammatory quinic acid derivatives for oral administration
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
JP5377329B2 (ja) * 2007-12-26 2013-12-25 Ｍｓｄ株式会社 スルホニル置換六員環誘導体
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2252598A2 (en) * 2008-02-11 2010-11-24 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009102460A2 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5538356B2 (ja) * 2008-03-18 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
TW200944526A (en) * 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
CA2723032A1 (en) * 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MX2010011935A (es) 2008-05-01 2011-05-19 Vitae Pharmaceuticals Inc Inhibidores ciclicos de 11 beta-hidroxiesteroide deshidrogenasa 1.
WO2009134392A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2010010150A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2324017B1 (en) 2008-07-25 2014-12-31 Boehringer Ingelheim International GmbH INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
JP5679997B2 (ja) 2009-02-04 2015-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
US8507493B2 (en) * 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
KR20120061771A (ko) * 2009-04-30 2012-06-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
EP2427465A1 (en) * 2009-05-07 2012-03-14 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
US8329904B2 (en) * 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8440710B2 (en) * 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2011056737A1 (en) 2009-11-05 2011-05-12 Boehringer Ingelheim International Gmbh Novel chiral phosphorus ligands
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
ES2706063T3 (es) 2010-02-11 2019-03-27 Univ Northwestern Agonistas del receptor de NMDA y usos del mismo
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8648192B2 (en) 2010-05-26 2014-02-11 Boehringer Ingelheim International Gmbh 2-oxo-1,2-dihydropyridin-4-ylboronic acid derivatives
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EA201300522A1 (ru) 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх Фармацевтические комбинации для лечения метаболических нарушений
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8722721B2 (en) * 2011-03-16 2014-05-13 Hoffmann-La Roche Inc. SEC-hydroxycyclohexyl derivatives
US8703807B2 (en) * 2011-03-17 2014-04-22 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds
RU2466995C1 (ru) * 2011-05-30 2012-11-20 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран Способ получения 2- и 4-(1,5,3-дитиазепинан-3-ил)фенолов
RU2467001C1 (ru) * 2011-05-30 2012-11-20 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран СПОСОБ ПОЛУЧЕНИЯ 3-(о-,м-,п-МЕТОКСИФЕНИЛ)-ТЕТРАГИДРО-2Н,6Н-1,5,3-ДИТИАЗОЦИНОВ
RU2467003C1 (ru) * 2011-05-30 2012-11-20 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран СПОСОБ ПОЛУЧЕНИЯ 3-(м-,п-МЕТИЛФЕНИЛ)-ТЕТРАГИДРО-2Н,6Н-1,5,3-ДИТИАЗОЦИНОВ
RU2466998C1 (ru) * 2011-06-09 2012-11-20 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран СПОСОБ ПОЛУЧЕНИЯ 3-(о-,м-,п-МЕТОКСИФЕНИЛ)-1,5,-3-ДИТИАЗЕПАНОВ
RU2466999C1 (ru) * 2011-06-16 2012-11-20 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран СПОСОБ ПОЛУЧЕНИЯ α,ω-БИС-(1,5,3-ДИТИАЗЕПИНАН-3-ИЛ)АЛКАНОВ
KR101589837B1 (ko) 2011-06-22 2016-01-29 퍼듀 퍼머 엘피 디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2565788C2 (ru) * 2011-09-30 2015-10-20 Учреждение Российской Академии Наук Институт Нефтехимии И Катализа Ран Способ получения n-(1,5,3-дитиазоцинан-3-ил)амидов
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
CA2878442A1 (en) 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
CN104968656B (zh) 2012-12-19 2017-08-11 诺华股份有限公司 自分泌运动因子抑制剂
BR112015018089B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor de nmda de espiro-lactama, composição farmacêutica os compreendendo e uso dos mesmos
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
HRP20190613T1 (hr) 2013-01-29 2019-06-28 Aptinyx Inc. Spiro-laktam modulatori nmda receptora i njihove uporabe
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EP2951185B1 (en) 2013-01-29 2016-12-21 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
PE20160845A1 (es) 2013-11-26 2016-09-10 Hoffmann La Roche Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
HUE046820T2 (hu) 2014-03-26 2020-03-30 Hoffmann La Roche Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként
CN105085525B (zh) * 2014-04-28 2019-01-04 南京明德新药研发股份有限公司 作为rho激酶抑制剂的异喹啉磺酰衍生物
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX377277B (es) 2015-09-04 2025-03-07 Hoffmann La Roche Derivados de fenoximetilo.
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
BR112018006034A2 (pt) 2015-09-24 2018-10-09 Hoffmann La Roche compostos bicíclicos como inibidores de atx
RU2725138C2 (ru) 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109415372B (zh) 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
MX388786B (es) 2016-08-01 2025-03-20 Aptinyx Inc Moduladores nmda espiro-lactam y métodos de uso de los mismos.
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Antiviral compounds
WO2023014828A2 (en) * 2021-08-03 2023-02-09 Mitochondria Emotion, Inc. Cyclopentane and cyclohexane variants of 6-phenylhexanamide mitofusin activators and methods for use thereof
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2114420A1 (de) * 1971-03-25 1972-10-05 Merck Patent Gmbh, 6100 Darmstadt Substituierte Phenylalkanol-Derivate und Verfahren zu ihrer Herstellung
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
TR18917A (tr) * 1974-10-31 1977-12-09 Ciba Geigy Ag 1-(bis-triflormetilfenil)-2-oksopirolidin-4-karbonik asitleri ve bunlarin tuerevleri
FR2312247A1 (fr) * 1975-05-30 1976-12-24 Parcor Derives de la thieno-pyridine, leur procede de preparation et leurs applications
US4439606A (en) * 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
US5206240A (en) * 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2705343B1 (fr) * 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
FR2724656B1 (fr) * 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
JP2000277478A (ja) * 1999-03-25 2000-10-06 Canon Inc 陽極化成装置、陽極化成システム、基板の処理装置及び処理方法、並びに基板の製造方法
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
WO2003000657A1 (en) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
AU2003211951A1 (en) * 2002-02-14 2003-09-04 Ono Pharmaceutical Co., Ltd. N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
WO2004035581A1 (ja) * 2002-10-18 2004-04-29 Ono Pharmaceutical Co., Ltd. スピロ複素環誘導体化合物およびその化合物を有効成分とする薬剤
WO2005047286A1 (ja) * 2003-11-13 2005-05-26 Ono Pharmaceutical Co., Ltd. スピロ複素環化合物
JP2007536369A (ja) * 2004-05-06 2007-12-13 ファイザー・インク プロリン及びモルホリン誘導体の新規化合物
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008504279A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
CA2570637A1 (en) * 2004-06-24 2006-02-02 Wenqing Yao N-substituted piperidines and their use as pharmaceuticals
US20050288338A1 (en) * 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
KR20070024639A (ko) * 2004-06-24 2007-03-02 인사이트 산 디에고 인코포레이티드 아미도 화합물 및 약제로서의 이의 용도
AU2005267331A1 (en) * 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006002361A2 (en) * 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
TW200626156A (en) * 2004-08-10 2006-08-01 Incyte Corp Amido compounds and their use as pharmaceuticals
NZ554906A (en) * 2004-11-10 2011-01-28 Incyte Corp Lactam compounds and their use as pharmaceuticals
BRPI0518281A2 (pt) * 2004-11-18 2008-11-18 Incyte Corp inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos
MX2007008239A (es) * 2005-01-05 2007-08-17 Abbott Lab Inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
MX2007010532A (es) * 2005-03-03 2007-10-12 Hoffmann La Roche Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
CA2606004A1 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
JP2009508963A (ja) * 2005-09-21 2009-03-05 インサイト・コーポレイション アミド化合物および医薬組成物としてのその使用
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
TW200804382A (en) * 2005-12-05 2008-01-16 Incyte Corp Lactam compounds and methods of using the same
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US20070197530A1 (en) * 2006-01-31 2007-08-23 Yun-Long Li Amido compounds and their use as pharmaceuticals
WO2007101270A1 (en) * 2006-03-02 2007-09-07 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP2013163A1 (en) * 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
EP2018378A2 (en) * 2006-05-17 2009-01-28 Incyte Corporation Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same

Also Published As

Publication number Publication date
WO2007103719A2 (en) 2007-09-13
WO2007103719A3 (en) 2008-01-24
TW200806629A (en) 2008-02-01
US20070208001A1 (en) 2007-09-06

Similar Documents

Publication Publication Date Title
AR059727A1 (es) Moduladores de 11- beta hidroxil esteriode deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos , y metodos de uso de los mismos
AR059726A1 (es) Moduladores de 11 beta hidroxil esteroide deshidrogenasa de tipo 1, composiciones farmaceuticas de los mismos, y metodos de uso de los mismos
AR083946A1 (es) Metodos de tratamiento con inhibidores selectivos de bcl-2
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
AR074306A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR068503A1 (es) Derivados de amidas sustituidas, composicion farmaceutica y usos.
AR083026A1 (es) Derivados de ciclohexenona y composiciones para el tratamiento del cancer de pulmon
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
AR082201A1 (es) Bencenosulfonamidas utiles como inhibidores del canal de sodio
AR071631A1 (es) Uso de un compuesto de quinilinil -4-oxi- fenil- ciclopropildicarboxamida y un inhibidor de erbb para preparar un medicamento util para el tratamiento de canceres
ECSP077417A (es) Nuevos derivados de aminopiridina que tienen acción inhibitoria selectiva de la aurora a
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR083798A1 (es) Inhibidores selectivos de glucosidasas y sus usos
AR051326A1 (es) Pirazolobenzodiazepinas disustituidas
AR086828A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR090398A1 (es) Inhibidores heterociclicos de glutaminasa
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
CO6180449A2 (es) Quinazolinonas y naftiridinonas que incluyen un grupo n-(bifenil-4-ilmetil-n-(piperidin-4-il)acetamida sustituida, utiles para el tratamiento de aterosclerosis
AR080859A1 (es) Derivados 1,2,4 triazolo-piridinicos inhibidores no nucleosidicos de la transcriptasa inversa, utiles para tratar infecciones por vih y composiciones farmaceuticas que los contienen.
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa

Legal Events

Date Code Title Description
FB Suspension of granting procedure